Viewing Study NCT04040361


Ignite Creation Date: 2025-12-24 @ 12:53 PM
Ignite Modification Date: 2026-05-14 @ 3:51 PM
Study NCT ID: NCT04040361
Status: UNKNOWN
Last Update Posted: 2022-04-06
First Post: 2019-07-29
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)
Sponsor: Masahiro Tsuboi
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Non-small Cell Lung Cancer Stage IB View
None Non-small Cell Lung Cancer Stage II View
None Non-small Cell Lung Cancer Stage ⅢA View
Keywords: